MC4R and neoplasm: Setmelanotide, an MC4R agonist, has demonstrated strong efficacy in aHO in a large double‐blind, randomized controlled phase 3 trial,28 following robust phase‐2 trial data showing a statistically significant proportion of tumor patients achieving ≥5% reduction in body mass index [BMI].29